Clinical trial
Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed…
NCT00046878 · Duke University, Other · Withdrawn
Key facts
| NCT number | NCT00046878 |
|---|---|
| Title | Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme |
| Official title | Phase 2 Trial of BCNU Plus O6-Benzylguanine (NSC 637037) in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | O6-benzylguanine, carmustine |
| Enrollment | 0 |
| Completion | Aug 1, 2002 |
| First posted | Aug 11, 2003 |
| Last update posted | Mar 28, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: